Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Liporaxel vs Taxol in First-line HER2-Negative Metastatic Breast Cancer
NCT03315364Phase 3Active, not recruiting
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Primary completion
- Feb 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of paclitaxel oral solution in breast cancer, sponsored by Daehwa Pharmaceutical Co., Ltd.. Started Dec 2017; status: active, not recruiting.
02
Drugs
paclitaxel oral solution
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03315364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315364.